Launch odevixibat
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- July 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Approval and launch expected H2 21”
What we found
Evidence strength A What the grades mean
The company received U.S. marketing approval for Bylvay (odevixibat) in July 2021, which falls within the H2 2021 commitment period.
-
A Albireo Pharma, Inc. 10-K filed 2022-03-01
“the approved product Bylvay has been granted a period of orphan drug exclusivity as a result of having been designated as an orphan drug for the treatment of PFIC prior to its U.S. marketing approval in July 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- odevixibat
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to regulatory approval
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Albireo Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C322505-023541 · Corrections policy